Alzheimer’s disease and aducanumab. What now?
Dates and Times
Start: 11/12/2021 8:00 AM
End: 11/12/2021 9:00 AM
- Explain the need for cognitive impairment screens in the context of new disease modifying therapies.
- Describe patient eligibility, medical infrastructure and workflow requirements for delivering disease modifying therapies.
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.